Wiley Bros. Aintree Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $14.9 Billion
- Q3 2025
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 2,743 shares of ALNY stock, worth $1.23 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,743
Previous 1,530
79.28%
Holding current value
$1.23 Million
Previous $498,000
151.0%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ALNY
# of Institutions
926Shares Held
117MCall Options Held
1.25MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...